Eli Lilly Reports Success With COVID-19 Neutralizing Antibody Treatment
Get ready for the best coronavirus news we've seen from the biopharmaceutical industry to date. An interim peek at a clinical trial with an experimental treatment from Eli Lilly (NYSE: LLY) suggests LY-CoV555 could be an effective treatment option for COVID-19 patients with mild-to-moderate symptoms.
The FDA has granted, and in some cases rescinded, emergency use authorizations for COVID-19 treatments that were around before SARS-CoV-2 made its debut in late 2019. If authorized, Lilly could launch the first treatment aimed directly at the novel coronavirus responsible for the pandemic. Back in March, Eli Lilly and its collaboration partner, AbCellera, isolated a pair of promising antibodies, LY-CoV555 and LY-CoV016, from a panel of more than 500 proteins found in blood samples of COVID-19 patients who recovered.
Image source: Getty Images.
Source Fool.com
